Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.

This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...

Karen Knudsen: Cancer prevention is one of the most critical challenges of our time / Abu Dhabi, Altagracia Gomez, Arthur C. Brooks, Bojan Obradović, cancer,

We show that aging is associated with an increase in the distance between nucleosomes, which can be used to predict a person's age and conduct age classification. We developed the first aging clock b...

A neuroscientist studying memory, I used to believe time was linear. Then my mother had a stroke.

Key Points. 1. Wildtype DNMT3A enhances TDG-mediated repair, whereas mutant DNMT3A impairs this process.2. Double mutant DNMT3A AML exhibits increased DNA

The Food and Drug Administration granted accelerated approval to encorafenib.

Laboratory-based Investigator, Faculty Search The Department of Medical Oncology at the Dana-Farber Cancer Institute (DFCI) and the Brigham and Wom...

Whether you’re just entering the workforce, starting a new job, or transitioning into people management, kindness can be a valuable attribute that speaks volumes about your character, commitment, and ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persis...

By Hadil Zureigat, MD, Third-Year Internal Medicine Resident, Cleveland Clinic, Aspiring Hematologist / Oncologist The cases that stick with us as doctors are not always the most medically interesting...